Evolution of cardiovascular risk after liver transplantation: A comparison of cyclosporine A and tacrolimus (FK506)

Canzanello, Vincent J.; Schwartz, Lora; Taler, Sandra J.; Textor, Stephen C.; Wiesner, R H; Porayko, Michael K.; Krom, R. A. F.

doi:10.1016/s0928-4346(97)85792-1

Cited by 17 publications

(37 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The cardiovascular morbidities of long-term steroid and calcineurin inhibitor use are well described, and reduction in them is integral to prolonged patient survival regardless of graft function (24)(25)(26). Freedom from steroids was achieved to an equivalent degree in both groups.…”

Section: Discussionmentioning

confidence: 91%

Four‐year follow‐up of a prospective randomized trial of mycophenolate mofetil with cyclosporine microemulsion or tacrolimus following liver transplantation

Fisher¹,

Stone²,

Wolfe³

et al. 2004

Clinical Transplantation

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 91%

Four‐year follow‐up of a prospective randomized trial of mycophenolate mofetil with cyclosporine microemulsion or tacrolimus following liver transplantation

Fisher¹,

Stone²,

Wolfe³

et al. 2004

Clinical Transplantation

View full text Add to dashboard Cite

show abstract

“…Hypertension after transplantation was observed more often with cyclosporin A than with tacrolimus and switching from cyclosporin A to tacrolimus improved post-transplant hypertension. 8,[26][27][28] Tacrolimus treatment may be better for patients who have risk factors such as old age, pretransplant obesity and pretransplant hypertension.…”

Section: Discussionmentioning

confidence: 99%

“…Cyclosporin A and steroids are risk factors of posttransplant dyslipidemia. 8,28,38,39 Dyslipidemia is a major risk factor of post-transplant cardiovascular events and mortality, 40 and the tacrolimus-based regimen may be better for patients with risk factors.…”

Section: Discussionmentioning

confidence: 99%

“…Notably, cyclosporin A and tacrolimus are associated with posttransplant hypertension, dyslipidemia and DM. [7][8][9][10] The use of steroids produces insulin resistance, which causes post-transplant DM in a dose-dependent manner. 10,11 Pretransplant assessment of risk factors of posttransplant metabolic abnormalities is necessary for the management of immunosuppressive regimens.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence and risk factors of obesity, hypertension, dyslipidemia and diabetes mellitus before and after adult living donor liver transplantation

Hara

Kawagishi

Nakanishi

et al. 2014

Hepatology Research

View full text Add to dashboard Cite

show abstract

“…[5][6][7] These complications have been attributed to immunosuppressive regimens and preexisting cardiac disease. 8,9 For this reason, LT candidates undergo an extensive preoperative cardiac assessment to ensure adequate function. 10,11 It is known that AF is associated with an increased risk of stroke, heart failure, and all-cause mortality in the general population; however, the impact of AF on patients undergoing LT is largely unknown.…”

mentioning

confidence: 99%

Preexisting atrial fibrillation and cardiac complications after liver transplantation

Bargehr

Trejo-Gutiérrez

Patel³

et al. 2015

Liver Transpl

View full text Add to dashboard Cite

Atrial fibrillation (AF) is the most common cardiac arrhythmia, and it is associated with increased cardiovascular morbidity and all-cause mortality. Our aim was to determine the impact of preexisting AF on patients undergoing liver transplantation (LT). A retrospective case-control study was performed. Records from patients who underwent LT between January 2005 and December 2008 at Mayo Clinic Florida were reviewed. Patients with preexisting AF were identified and matched to patients who did not have a diagnosis of AF. Thirty-two of 717 LT recipients (4.5%) had AF before LT. These patients were compared to a control group of 63 LT recipients. Pre-LT left ventricular hypertrophy (P 5 0.03), a history of congestive heart failure (P 5 0.04), and a history of stroke or transient ischemic attack (P 5 0.03) were significantly more prevalent in patients with AF versus controls. Intraoperative adverse cardiac events (P 5 0.02) and AF-related adverse postoperative events (P < 0.001) were more common in the recipients with known AF. Six patients with paroxysmal AF (19%) developed chronic/ persistent AF postoperatively. Graft survival and patient survival were similar in the groups. Although patients with AF had a higher incidence of intraoperative cardiac events, a higher cardiovascular morbidity rate, and a complicated postoperative course, this did not affect overall graft and patient survival. Liver Transpl 21:314-320, 2015. V C 2014 AASLD. Atrial fibrillation (AF) is the most common cardiac arrhythmia with an estimated incidence of 28.3 per 1000 person-years in the United States. 1 The prevalence of AF is 0.95% to 2.3% in the general population; however, it is more prevalent in men and older individuals. 2-4 AF affects approximately 2.3 million Americans, and it is projected that more than 5.6 million Americans will have this condition by 2050. 3 Liver transplantation (LT) outcomes have improved in the last 2 decades, but cardiovascular complications remain a leading cause of death in LT recipients. 5-7 These complications have been attributed to immunosuppressive regimens and preexisting cardiac disease. 8,9 For this reason, LT candidates undergo an extensive preoperative cardiac assessment to ensure adequate function. 10,11 It is known that AF is associated with an increased risk of stroke, heart failure, and all-cause mortality in the general population; however, the impact of AF on patients undergoing LT is largely unknown. 12,13 Our aim in this study was to determine the morbidity and mortality associated with AF in patients undergoing LT. PATIENTS AND METHODSA retrospective analysis was performed of all patients who underwent LT between January 2005 and December 2008 at our institution. This study was reviewed

show abstract

Evolution of cardiovascular risk after liver transplantation: A comparison of cyclosporine A and tacrolimus (FK506)

Cited by 17 publications

References 8 publications

Four‐year follow‐up of a prospective randomized trial of mycophenolate mofetil with cyclosporine microemulsion or tacrolimus following liver transplantation

Four‐year follow‐up of a prospective randomized trial of mycophenolate mofetil with cyclosporine microemulsion or tacrolimus following liver transplantation

Prevalence and risk factors of obesity, hypertension, dyslipidemia and diabetes mellitus before and after adult living donor liver transplantation

Preexisting atrial fibrillation and cardiac complications after liver transplantation

Contact Info

Product

Resources

About